Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research · Journal article
Cellular and Molecular Life Sciences · August 26, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical study demonstrating that CRISPR-engineered iPSC-derived mesenchymal stromal cells producing FVIII and expressing CD47 show hypoimmunogenic properties and ameliorate bleeding in a hemophilia A mouse model. The work presents early-stage proof-of-concept for a cell-based gene therapy strategy but provides no human efficacy or safety data and lacks comparative controls.
Preclinical in vitro and in vivo efficacy study in animal models. Immunodeficient mice and hemophilia A mouse model; engineered iMSCs derived from human iPSCs.. Intervention: Engineered iMSCs expressing codon-optimized B domain-deleted FVIII and CD47, administered intravenously, intramuscularly, or via transplantation.
Engineered iMSCs secreted functional FVIII at 1271 ng/10^6 cells/48 h Engineered iMSCs exhibited hypoimmunogenic properties both in vitro and in vivo Transplantation into HA mice significantly increased plasma FVIII activity and ameliorated bleeding phenotype
No human efficacy, pharmacokinetics, or safety data provided Transplantation into HA mice significantly increased plasma FVIII activity and ameliorated bleeding phenotype
This preclinical work is not yet ready to inform clinical practice. Human translation requires demonstration of sustained FVIII expression, safety profile, and efficacy in clinical trials before adoption into standard hemophilia A management.
Preclinical proof-of-concept in animal models using engineered iPSC-derived cells; lacks human efficacy data, safety follow-up, and dose-response characterization needed to support clinical translation.
As stated by the source record.
This preclinical work is not yet ready to inform clinical practice. Human translation requires demonstration of sustained FVIII expression, safety profile, and efficacy in clinical trials before adoption into standard hemophilia A management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Cell-based gene therapy represents a promising therapeutic avenue for genetic diseases such as hemophilia A (HA). However, clinical translation is limited by low transgene expression and host immune responses. Methods: Using CRISPR/Cas9, we targeted a codon-optimized B domain-deleted F8 gene along with CD47 into the B2M locus in human induced pluripotent stem cells (iPSCs) and differentiated these cells into mesenchymal stromal cells (iMSCs). The immunogenicity of the engineered iMSCs was tested and the therapeutic efficacy was investigated in immunodeficient mice and in an HA mouse model. Findings: The engineered iMSCs secreted functional FVIII at high concentrations (1271 ng/106 cells/48 h) and exhibited hypoimmunogenic properties both in vitro and in vivo. In immunodeficient mice, both intravenous and intramuscular administration were shown to be effective. Transplantation of engineered iMSCs into HA mice significantly increased plasma FVIII activity and ameliorated the bleeding phenotype. Interpretation: We describe a universally applicable hypoimmunogenic cell-based gene therapy strategy for HA and other genetic diseases by targeting a codon-optimized B domain-deleted F8 gene along with CD47 into the B2M locus in human iPSCs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.